Analyst Ananda Ghosh of H.C. Wainwright maintained a Buy rating on PepGen Inc., retaining the price target of $8.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ananda Ghosh has given his Buy rating due to a combination of factors that highlight PepGen Inc.’s promising clinical developments and strategic decisions. The recent completion of dosing in the FREEDOM-DM1 trial’s 15 mg/kg cohort is a significant milestone, with the company reporting robust splicing correction and favorable safety data at lower doses. This progress supports the transition to the FREEDOM2-DM1 Phase 2 study, potentially accelerating the clinical timeline by several months.
Ananda Ghosh’s confidence is further bolstered by the dose-dependent increase in splicing correction observed in the trial, which is expected to translate into clinical benefits. The safety profile of PepGen’s EDO platform, showing no adverse effects in critical biomarkers, adds to the positive outlook. With upcoming data readouts and the potential for acquisition interest in the growing DM1 market, PepGen’s strategic focus and clinical advancements make it a compelling Buy recommendation.
According to TipRanks, Ghosh is a 3-star analyst with an average return of 8.8% and a 55.56% success rate. Ghosh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, ACADIA Pharmaceuticals, and Avidity Biosciences.